Drug Profile

Research programme: antimalarials - Sanofi

Latest Information Update: 31 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Broad Institute; Genzyme Corporation; Harvard University
Developer Broad Institute; Harvard University; Medicines for Malaria Venture; Sanofi
Class
Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Heat-shock protein inhibitors; Histone deacetylase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in USA
08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
31 Dec 2010 This programme is still in active development

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com